Olive Oil Polyphenol Absorption: At Least 55% of a Dose Gets In

Whether the body absorbs olive oil polyphenols is the question every other claim about them rests on. In 2002, a team at Wageningen University answered it directly in The Journal of Nutrition. Maud Vissers and colleagues gave 100 mg of olive oil phenols to eight people with an ileostomy, collected everything that left the small intestine over the next 24 hours, and measured what was missing. At least 55 to 66 percent of the dose had been taken up, and tyrosol and hydroxytyrosol in urine confirmed it.

Why This Study Matters

A line repeated across nutrition writing holds that dietary polyphenols are poorly absorbed, that most of what you swallow travels intact to the colon. For several families of plant compounds that is roughly accurate. For olive phenols it is not, and this is the paper that established the difference.

The reason earlier work could not settle it is a measurement problem. Blood and urine tell you what got through. They cannot distinguish a compound that was never absorbed from one that was absorbed and then converted into something the assay was not looking for. Both look like absence.

An ileostomy removes that ambiguity. In people whose colon has been surgically removed, the contents of the small intestine leave the body into a collection bag instead of passing onward. Whatever the small intestine declined to take up can be collected and quantified rather than inferred. Feed a known dose, weigh what comes out, and the difference is the upper bound on what stayed in.

There was a second reason to run the experiment. Olive oil does not carry one phenol, it carries several with quite different chemistry. The most abundant are the nonpolar oleuropein and ligstroside aglycones, alongside the polar simple phenols hydroxytyrosol and tyrosol. Those are different molecules with different solubility, and there was no reason to assume the gut treats them alike. The trial tested them separately.

How It Was Designed

Eight healthy ileostomy subjects took part in the absorption measurement. A second group of 12 volunteers with an intact colon took part in the urinary work, which gave the researchers a comparison between people who have a colon and people who do not.

Each participant consumed three different supplements on separate days in random order, and every supplement delivered the same 100 mg of olive oil phenols. The ileostomy subjects received one supplement containing mainly nonpolar phenols, one containing mainly polar phenols, and one containing oleuropein glycoside, the parent compound those phenols derive from. The subjects with a colon received the nonpolar and polar supplements and, in place of the oleuropein glycoside, a phenol free placebo. That placebo day matters: it establishes how much tyrosol and hydroxytyrosol appear in urine with no dose given, which is the baseline every other number is read against.

Ileostomy effluent and urine were collected for 24 hours after each intake. The design therefore runs two comparisons at once. Within the ileostomy group, three chemical forms of the same dose reveal whether form changes the outcome. Across the two groups, the same two supplements reveal what having a colon changes.

What They Found

Very little of the swallowed dose left the small intestine, and what did leave was not in the form it went in as.

Figures are molar percentages of the ingested dose: out of every 100 molecules swallowed, how many were accounted for. Green marks the measurements that demonstrate uptake.

Reading the Results

What did not come out is the finding. Tyrosol and hydroxytyrosol together accounted for under 4 molecules per 100 swallowed in the ileostomy effluent, and the aglycones were not detectable at all. Something had happened to them inside the small intestine. The authors put the apparent absorption at 55 to 66 percent of the dose and framed that as a floor rather than an estimate, because a molecule broken down in the gut lumen and a molecule taken up across the gut wall both disappear from the bag the same way. The urinary data are what separate those two possibilities, and they point to genuine uptake.

Urine confirmed absorption without accounting for it. Between 5 and 16 molecules per 100 came back as tyrosol or hydroxytyrosol in 24 hour urine, depending on the supplement and the group. Set that against absorption of 55 percent or more and a gap opens up that is larger than either number. The authors' own conclusion names it: absorbed olive oil phenols are extensively modified in the body. They are not excreted as themselves. A small phenol meeting that fate is unremarkable, and it explains why the parent compound is a poor thing to hunt for in blood. Later work followed the molecules further downstream and found the products, including the phenolic acids that rise in urine after an eight week olive polyphenol intervention, and the enzymatic conversion of tyrosol into hydroxytyrosol inside the body.

The colon made a difference in one comparison and not the other. From the nonpolar supplement, ileostomy subjects excreted 12 molecules per 100 as the simple phenols while subjects with a colon excreted 6. From the polar supplement, both groups sat at 5 to 6. The difference is worth reporting and worth not overreading: these are two separate small groups rather than the same people measured twice, and the study was not built to isolate the colon's contribution. What it does establish is that the colon is not where the absorption story begins. By the time intestinal contents would have reached it, most of the dose was already gone.

The parent compound performed best. Oleuropein glycoside, the intact form that occurs in the olive before processing, produced the highest urinary recovery of the three supplements at 16 molecules per 100, and it came back mainly as hydroxytyrosol. The glycoside was cleaved somewhere along the way and its hydroxytyrosol half was absorbed and excreted. Chemical form changed the numbers. It did not change the conclusion.

What the Study Did Not Show

No health outcome was measured. There are no lipid results here, no oxidative stress markers, no blood pressure, no clinical endpoint of any kind. The paper is about where molecules go, and it makes no claim about what they do once they arrive. The evidence for effect sits in other trials, including the 200 man EUROLIVE crossover and the meta-analysis pooling 26 randomized trials, and in the EFSA health claim that those trials support.

It also did not test olive oil. Participants swallowed supplements formulated to isolate phenol classes, which is the only way to answer the question the study asked, and it means the numbers describe those preparations rather than a tablespoon of extra virgin olive oil. What the food a phenol arrives in does to its absorption was measured later, in a 20 person trial comparing the same 5 mg dose across six different matrices, where olive oil itself came out ahead of yogurt and water.

And it cannot describe what reaches the colon in a person who has one. The ileostomy model ends at the end of the small intestine by design. The colonic half of the story had to be measured a different way, by looking for microbial breakdown products in people with intact digestive tracts, and it has been.

Limits and What's Still Unknown

The groups were small, at eight and twelve people, and each measurement rests on a single dose followed for 24 hours. Nothing here speaks to what happens when the same compounds arrive daily for weeks.

The dose was also a research dose rather than a serving. Twenty grams of an oil testing at 1,000 mg of phenolic compounds per kilogram supplies about 20 mg, so 100 mg in one sitting is several times what even a high phenolic olive oil delivers in a day. Absorption percentages measured at a high single dose do not automatically hold at lower ones.

People living with an ileostomy are also not a general population. Transit time differs, the resident microbial community differs, and the surgery that made the measurement possible is the same surgery that makes the model imperfect. That trade is inherent to this method and the authors were explicit about working within it.

Finally, apparent absorption is a subtraction, not a direct observation of uptake. It is the strongest available human measurement of the question, and it is still a subtraction.

Broader Context

This paper is the reason a common piece of polyphenol shorthand is wrong when applied to olives. The claim that most polyphenols pass through unabsorbed comes largely from flavonoid research, where it often holds. Olive phenols are smaller, simpler molecules and they behave differently, sitting among the better absorbed compounds in the dietary polyphenol literature. The accurate version of the sentence is that a majority is absorbed in the small intestine and a portion, together with the metabolites the body makes from it, continues into the colon where bacteria keep working on it.

Everything measured since has been built on top of that. Population work uses urinary phenols as a marker of intake precisely because they appear there reliably, which is what makes something like the urinary polyphenol signature identified within PREDIMED possible at all. Trials that enrich a food with hydroxytyrosol assume the enrichment will be taken up. The EFSA claim is written as a threshold in the oil, 5 mg of hydroxytyrosol and its derivatives per 20 g, which only makes sense if what is in the oil gets into the person.

For the plain language version of where this leaves the everyday questions, see what we know about taking olive oil on an empty stomach and whether olive oil is good for gut health. The short answer both pieces arrive at starts here: the compounds get in, so the polyphenol number on the bottle is the variable that matters.

Related Research

Continue exploring olive oil and polyphenol science:

• Why the EVOO Matrix Matters: 20-Person Bioavailability Trial on Hydroxytyrosol
• The Tyrosol to Hydroxytyrosol Conversion: A Human RCT
• Olive Polyphenols Reached the Colon: An 8-Week Trial in 62 Adults
• What Is Hydroxytyrosol? Olive Oil's Most Studied Compound

Source: View the original study on PubMed

Olivea's Dosage

This study used 100 mg of olive oil phenols in a single supplement dose, chosen to make the measurement possible rather than to model a serving. Olivea works at dietary scale: each Olivea capsule delivers over 20 mg of hydroxytyrosol, and our most recent third party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study: we did not fund it, design it, or conduct it, and it did not test an Olivea product.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.